Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
<p>Abstract</p> <p>Background</p> <p>Ipilimumab induces long-lasting clinical responses in a minority of patients with metastatic melanoma. To better understand the mechanism(s) of action and to identify novel biomarkers associated with the clinical benefit and toxicity...
Main Authors: | Wang Wenshi, Yu Daohai, Sarnaik Amod A, Yu Bin, Hall Maclean, Morelli Dawn, Zhang Yonghong, Zhao Xiuhua, Weber Jeffrey S |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-07-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | http://www.translational-medicine.com/content/10/1/146 |
Similar Items
-
IPILIMUMAB IN THERAPY OF METASTATIC MELANOMA
by: I. V. SAMOILENKO, et al.
Published: (2016-12-01) -
Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
by: Nethanel Asher, et al.
Published: (2020-08-01) -
Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab
by: Philip Friedlander, et al.
Published: (2017-08-01) -
Clinical benefit from ipilimumab therapy in melanoma patients may be associated with serum CTLA4 levels
by: Anna M. Leung, et al.
Published: (2014-05-01) -
Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
by: Amirali Karimi, et al.
Published: (2021-03-01)